Ferreiro Esteban, de Uralde Belén López, Abreu Rita, García-Velasco Juan A, Muñoz Elkin
IVIRMA Vigo, Plaza Francisco Fernandez del Riego, 7 36203, Vigo Pontevedra, Spain.
IVIRMA Coruna, Plaza Francisco Fernandez del Riego, 7 36203, Vigo Pontevedra, Spain.
Curr Drug Targets. 2020;21(9):910-921. doi: 10.2174/1389450121666200220124607.
Breast cancer is the most common malignancy diagnosed in women, and its treatment has a high probability of loss of fertility. Oocyte vitrification is the most commonly used technique to preserve fertility before starting oncological treatment. Aromatase inhibitors induce hypoestrogenemia while promoting the release of gonadotropins and constitute an alternative drug for ovarian stimulation in patients with breast cancer.
In this mini-review, we update and describe the current status of aromatase inhibitor use in controlled ovarian stimulation for oocyte vitrification in patients with breast cancer.
Aromatase inhibitors are commonly used in combination with gonadotropins for ovarian stimulation in patients with breast cancer who preserve their fertility through oocyte vitrification. They achieve similar ovarian responses as conventional ovarian stimulation protocols in regards to the number of oocytes, and no additional complications after their use have been reported. Furthermore, aromatase inhibitors seem to be safe not only for offspring, as no more congenital defects occur in newborns from pregnancies achieved after their use, but also for the patients, as no more malignancy recurrence or increased mortality was found in cohort studies.
Aromatase inhibitors are elective drugs for ovarian stimulation in patients with breast cancer who decide to preserve their fertility through oocyte vitrification.
乳腺癌是女性中最常见的诊断出的恶性肿瘤，其治疗很有可能导致生育能力丧失。卵母细胞玻璃化冷冻是在开始肿瘤治疗前保存生育能力最常用的技术。芳香化酶抑制剂在促进促性腺激素释放的同时会诱发低雌激素血症，是乳腺癌患者卵巢刺激的替代药物。
在本综述中，我们更新并描述了芳香化酶抑制剂在乳腺癌患者卵母细胞玻璃化冷冻的控制性卵巢刺激中的应用现状。
芳香化酶抑制剂通常与促性腺激素联合用于通过卵母细胞玻璃化冷冻来保留生育能力的乳腺癌患者的卵巢刺激。在卵母细胞数量方面，它们与传统卵巢刺激方案的卵巢反应相似，且使用后未报告有额外并发症。此外，芳香化酶抑制剂似乎不仅对后代安全，因为使用后受孕的新生儿中先天性缺陷并未增加，而且对患者也安全，因为在队列研究中未发现恶性肿瘤复发或死亡率增加。
对于决定通过卵母细胞玻璃化冷冻来保留生育能力的乳腺癌患者，芳香化酶抑制剂是卵巢刺激的首选药物。
